IGKV4-1 (B3) as A Drug Target for Neurological Disorders (G28908)

Target Name: IGKV4-1

NCBI ID: G28908

Other Name(s): B3 | IGKV41 | Immunoglobulin kappa variable 4-1 | immunoglobulin kappa variable 4-1

IGKV4-1 (B3) as A Drug Target for Neurological Disorders

IGKV4-1 (B3) is a protein that is expressed in the brain and is known for its role in the regulation of ion channels. It is a potential drug target (or biomarker) that can be targeted with small molecule inhibitors.

IGKV4-1 (B3) is a transmembrane protein that is expressed in the brain and is involved in the regulation of various ion channels, including the potassium ion channel. It is a key protein that is involved in the regulation of the activity of these channels , which are responsible for the flow of ions into and out of the cells.

One of the unique features of IGKV4-1 (B3) is its expression pattern in the brain. It is primarily expressed in the prefrontal cortex, which is the part of the brain that is responsible for various higher-order cognitive functions. This suggests that IGKV4-1 (B3) plays an important role in the function of the brain.

In addition to its expression in the brain, IGKV4-1 (B3) is also involved in the regulation of ion channels in other tissues. It is expressed in various types of neurons, including those in the heart and the pancreas. This suggests that IGKV4 -1 (B3) is involved in the regulation of ion channels in a variety of tissues and that it may be a useful drug target.

The potential benefits of targeting IGKV4-1 (B3) as a drug target are numerous. One of the main advantages is that it is a protein that is primarily expressed in the brain, which makes it a potentially effective target for drugs that can inhibit its activity in this tissue. In addition, IGKV4-1 (B3) is involved in the regulation of a variety of ion channels, which makes it a potentially useful target for drugs that can inhibit its activity in other tissues.

Targeting IGKV4-1 (B3) as a drug target can also have the advantage of increasing our understanding of the underlying mechanisms of the disease. For example, by inhibiting its activity, drugs can potentially help to reduce the activity of ion channels in the brain and improve the symptoms of various neurological disorders. This can help to identify new targets for therapies and may lead to the development of new treatments for these disorders.

In conclusion, IGKV4-1 (B3) is a protein that is expressed in the brain and is involved in the regulation of various ion channels. It is a potential drug target (or biomarker) that can be targeted with small molecule inhibitors. While more research is needed to fully understand its role in the brain and its potential as a drug target, its expression in the brain and its involvement in the regulation of ion channels make it a promising target for future research.

Protein Name: Immunoglobulin Kappa Variable 4-1

Functions: V segment of the variable domain of immunoglobulins light chain that participates in the antigen recognition (PubMed:24600447). Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens (PubMed:22158414, PubMed:20176268). The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation for a particular antigen (PubMed:20176268, PubMed:17576170)

More Common Targets